ilumya
(tildrakizumab-asmn)Sun Pharmaceutical Industries, Inc.
Usage: ILUMYA® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who qualify for systemic therapy or phototherapy.
9 results
omvoh
(mirikizumab-mrkz)Eli Lilly and CompanyUsage: OMVOH is indicated for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease in adults.pyzchiva
(ustekinumab-ttwe)SANDOZ INCUsage: PYZCHIVA is indicated for adults and pediatric patients aged 6 and older with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis. It is designed for patients suitable for phototherapy or systemic therapy.selarsdi
(ustekinumab-aekn)Teva Pharmaceuticals USA, Inc.Usage: SELARSDI™ is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis in the same age group, and moderately to severely active Crohn’s disease and ulcerative colitis in adults.skyrizi
(Risankizumab-rzaa)AbbVie Inc.Usage: SKYRIZI® is indicated for the treatment of moderate-to-severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis in adults.stelara
(ustekinumab)Janssen Biotech, Inc.Usage: STELARA® is indicated for treating moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients aged 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.ustekinumab
(ustekinumab)Janssen Biotech, Inc.Usage: Ustekinumab is indicated for adults and pediatric patients aged 6 and older with moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and moderately to severely active ulcerative colitis, particularly those suitable for phototherapy or systemic therapy.ustekinumab-ttwe
(ustekinumab-ttwe)Quallent Pharmaceuticals Health LLCUsage: Ustekinumab-ttwe is indicated for the treatment of moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.yesintek
(ustekinumab)Biocon Biologics Inc.Usage: YESINTEK is indicated for treating moderate to severe plaque psoriasis in patients aged 6 and older, active psoriatic arthritis in patients 6 and older, and moderately to severely active Crohn's disease and ulcerative colitis in adults.